ClinicalTrials.gg
Not yet recruitingNCT07294430OASISImmunoPETUpdated Jul 31, 2026

Antibody-based PET Imaging and Treatment Response in Breast Cancer Treated With an Antibody-drug Conjugate.

A Phase 2 interventional study of Immuno-PET in Locally Advanced or Metastatic Breast Cancer, sponsored by UNICANCER. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by UNICANCER · Phase 2, Interventional, and Basic science

How we know · 3 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 64 studies in Breast Neoplasms by UNICANCER — 15 open to participants now, 27 under way, 7 of them phase 3. Breast Neoplasms · UNICANCER.

Planned enrollment
55th of 59
30 · median 170
Started
2026
with 5 others
Phase 2
28 of 64
8 open now
Primary completion
2028-12
later than 15 of 26 live
Registered
62nd of 64
by date

Among the 64 studies in Breast Neoplasms by UNICANCER, this one is the 55th largest by planned enrollment of the 59 interventional ones that give a count, is one of 6 that started in 2026, is one of 28 in phase 2, reaches primary completion later than 15 of the 26 other live ones, and was the 62nd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

15 of the 64 studies in Breast Neoplasms by UNICANCER are open now, in 9 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Breast Neoplasms by UNICANCER, or all of them as a file.
02

Study summary

OASIS-ImmunoPET is a monocentric pilot study evaluating antibody imaging to predict response to antibody-drug conjugate (ADC), an innovative cancer targeted therapy, and potentially replace tumor biopsy. It is addressed to patients with locally advanced or metastatic breast cancer who are eligible to receive the ADC Trastuzumab deruxtecan (T-DXd) according to local approval, and who are already enrolled in OASIS study (NCT pending).

Read the detailed description

Antibody-drug conjugates (ADCs) have emerged as a transformative class of cancer targeted therapies, combining the specificity of monoclonal antibodies with the potency of cytotoxic payloads. This dual mechanism allows ADCs to selectively target tumor cells while minimizing systemic toxicity, thereby offering a more refined approach compared to conventional chemotherapy.

ADCs are made of 3 components: a monoclonal antibody specifically targeting tumor cells, a highly potent cytotoxic payload, and a special linker that connects the antibody to the drug. Their multi-step mode of action implies that ADC activity relies on multiple factors, such as target distribution, target density, internalization capability, linker cleavage, payload sensitivity and tumor-microenvironment modulation.

Over the past decade, ADCs have demonstrated significant improvements in survival for patients with various solid tumors and hematological malignancies. Despite these advancements, resistance to ADCs remains a major clinical challenge. Most patients who initially respond to ADC therapy eventually develop resistance, leading to disease progression. The mechanisms underlying ADC resistance are complex and poorly understood, involving tumor heterogeneity, drug metabolism, immune evasion, and alterations in target antigen expression.

Currently, no validated predictive biomarkers exist to guide ADC selection, treatment sequencing, or resistance monitoring. As a result, clinicians lack reliable tools to personalize ADC therapy, limiting the ability to optimize patient outcomes. A deeper understanding of ADC response and resistance mechanisms is urgently needed to define and adopt optimal companion diagnostics for currently approved and forthcoming ADCs and to obtain decision support tools for selecting the optimal ADC for each patient.

The protocol OASIS (NCT pending) aims to define optimal assays for predicting resistance to several approved ADCs in patients treated according to standard indications. The OASIS-ImmunoPET protocol will explore the potential contribution of advanced molecular imaging to identify response to treatment in patients enrolled in the OASIS study.

The advent of ImmunoPET combines the high sensitivity and resolution of positron emission tomography (PET) with the specificity of monoclonal antibodies (mAb) or mAb-associated fragments used as radiotracers and as such provides a comprehensive characterization of the target distribution and the target engagement over the whole-body tumor burden labeling. ⁸⁹Zr is by far the most frequently used positron-emitting nuclide for antibody.

Gebhart et al. (2016) showed the value of adding [⁸⁹Zr]-Trastuzumab PET imaging to biopsies for the assessment of intrapatient tumor heterogeneity and for prediction of the treatment outcome in HER2-positive breast cancer patients treated with Trastuzumab emtansine (T-DM1).

This OASIS-ImmunoPET study is considered a pilot sub-study of OASIS and is designed to evaluate the association between [⁸⁹Zr]-Trastuzumab PET and response in patients with HER2-positive and HER2-low breast cancer treated with T-DXd, an ADC that was developed to target HER2-expressing cancers. We aim to explore whether resistance to T-DXd is dependent on target antigen loss or heterogeneity across tumor sites and whether there is a correlation between HER2 expression level on the tumor biopsy as determined by immunohistochemistry (IHC) and HER2 PET to understand whether Ab-radiolabelled PET scan can be used as a surrogate of tumor biopsy or treatment outcome.

Both [⁸⁹Zr]-Trastuzumab PET imaging and control FDG-PET imaging will be performed at two time points: at Baseline and at End of treatment (i.e. discontinuation for any reason). Additional control FDG-PET alone will be performed just before cycle 2 (for evaluation early response), and then every 3 cycles according to standard routine.

03

Conditions studied

  • Locally Advanced or Metastatic Breast Cancer

Browse trials for

Keywords

  • Advanced molecular imaging
  • ADC
  • Response
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient must have signed a written prior to any trial specific procedures. When the patient is physically unable to give their written consent, a trusted person of their choice, independent from the investigator or the sponsor, can confirm in writing the patient's consent;
  2. Patients enrolled in the prospective cohort of the OASIS study;
  3. Patient with locally advanced or breast cancer eligible to receive T-DXd as part of their standard care;
  4. At baseline imaging at least two "target" lesions fulfilling the following criteria: (1) anatomically transaxial diameter ≥ 1.5 cm and measurable per RECIST1.1. and (2) metabolically assessable with a maximum standard uptake value corrected for lean body mass (SUVmax) ≥ 1.5 x SUVmean + 2 standard deviations (SD) of the liver measured in a 3-cm-diameter spherical volume of interest (VOI) in normal liver parenchyma;
  5. Patients must be willing and able to comply with the protocol for the duration of the trial;

Exclusion criteria

Exclusion Criteria:

  1. Patients already treated with Trastuzumab deruxtecan (T-DXd);
  2. at the ImmunoPET radioligands injection;
  3. Patients who are claustrophobic or unable to remain still for 30 minutes;
  4. Female participant who is pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 90 days after the final administration of study treatment;
  5. Person deprived of their liberty or under protective custody or guardianship.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Locally advanced or metastatic breast cancer treated with Trastuzumab deruxtecan (T-DXd)

    Experimental advanced molecular imaging (ImmunoPET) combining the high sensitivity and resolution of positron emission tomography (PET) with the specificity of ADC target specific monoclonal antibodies.

    Procedure: Immuno-PET

Interventions

  • ProcedureImmuno-PET

    Realization of an advanced molecular imaging exam to visualize the T-DXd target (HER2) expression throughout the body, at baseline and at treatment discontinuation. This procedure relies on the administration to the patient of a radioactive tracer \[89Zr\]-anti-HER2. This experimental imaging is associated to standard FDG-PET scans for tumor assessment.

This study also gives Trastuzumab deruxtecanStudies of Trastuzumab deruxtecanTrastuzumab deruxtecan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Metabolic objective response rate

    Metabolic objective response rate (ORR) is defined as the proportion of patients who achieved a confirmed complete metabolic response (CR) or partial metabolic response (PR) assessed by investigators according to PERCIST 1.0 after 3 cycles of treatment initiation.

    Time frame: From treatment initiation to disease progression, up to 3 cycles of treatment (each cycle is 21 to 28 days).

Secondary outcomes

  1. Metabolic objective response rate (ORR) at 6 months

    Metabolic objective response rate (ORR) is defined as the proportion of patients who achieved a confirmed complete metabolic response (CR) or partial metabolic response (PR) assessed by investigators according to PERCIST 1.0 after 6 months of treatment.

    Time frame: From treatment initiation to disease progression, up to 6 months of treatment

  2. Radiological objective response rate (ORR)

    Radiological ORR is defined as the proportion of patients who achieved a confirmed complete radiological response (CR) or partial radiological response (PR) assessed by investigators according to RECIST 1.1 after 3 cycles and 6 months of treatment initiation.

    Time frame: From treatment initiation to objective response, up to 6 months

  3. Progression-Free Survival (PFS)

    Progression-Free Survival (PFS) is defined as the time from treatment initiation to the first documented radiological or metabolic progression of disease or death, whatever the cause. Patients still alive at the cut-off time without documented progression (including lost to follow-up) will be censored at the time of the latest evaluable efficacy assessment.

    Time frame: From treatment initiation to disease progression or death, up to 3 years

  4. Radiological progression-free survival (PFS)

    Radiological PFS defined as time from treatment initiation to the first documented radiological or progression of disease or death, whatever the cause.

    Time frame: From treatment initiation to disease progression or death, up to 3 years

  5. Overall Survival (OS)

    Overall Survival (OS) is defined as the time from inclusion to death due to any cause. Patients still alive at the cut-off time (including lost to follow-up) will be censored at the last known alive date.

    Time frame: From treatment initiation to death from any cause, up to 5 years

  6. Time to detection of brain metastases

    Time to detection of brain metastases as identified by \[⁸⁹Zr\]-Trastuzumab - PET vs standard modality (brain CT/MRI, patients' symptoms, clinical examen: presence of new or progressive lesions in the brain, confirmed by radiological imaging. Detection is considered the first instance in which metastases are identified through either \[⁸⁹Zr\]-Trastuzumab - PET or standard modality (brain CT/MRI, patients' symptoms, clinical examen).

    Time frame: From treatment initiation to brain metastasis onset, up to 5 years

  7. Proportion of patients with change in the pattern from baseline to progression or end of treatment

    Proportion of patients with change in the pattern from baseline to progression or end of treatment. A positive pattern means that the entire or majority of the tumour load shows significant tracer uptake, whereas a negative pattern means the dominant part or all of the tumour load lacks significant tracer uptake.

    Time frame: From treatment initiation to disease progression or death, up to 3 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 24 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2025
First posted
Dec 19, 2025
StartEst.
Dec 31, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2030
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07294430
Lead sponsor
UNICANCER
Responsible party
Sponsor
First posted
Dec 19, 2025
Start date
Dec 31, 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Jul 31, 2026

Study contacts

Marjorie Mauduit
Contact
m-mauduit@unicancer.fr
0630481792 ext. +33
Jérôme Lemonnier
Contact
j-lemonnier@unicancer.fr
Barbara Pistilli, MD, PhD
principal investigator · Gustave Roussy Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion